Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: David Martinez Selva
Collaborators: Rafael Simó Canonge, Cristina Hernández Pascual
Funding agency: Instituto de Salud Carlos III
Funding: 42000
Reference: CP08/00058
Duration: 01/01/2009 - 31/12/2011

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 247050
Reference: MS08/00058
Duration: 01/02/2009 - 31/01/2015

Unidad Central de Investigación en Ensayos Clínicos Vall d'Hebron (UCIEC-VH)

IP: Rafael Simó Canonge
Collaborators: Manuel Hernández González, Joan Montaner Villalonga, Mercè Boada Rovira, Ramon Charco Torra, José García Arumí, Albert Pahissa Berga, Josep Sánchez de Toledo Codina, Juan Lorente Guerrero, Miquel Casas Brugué, Monica Anglada Baguena, Miguel Vilardell Tarres, Sara Marsal Barril, Joan Sahuquillo Barris, Cristina Hernández Pascual, Ester Carceller Delgado, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 781267.51
Reference: CAI08/01/0034
Duration: 01/01/2009 - 31/12/2012

CIBER: Diabetes y Enfermedades Metabólicas

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual, Monica Higuera Urbano
Funding agency: CIBER Diabetes y Enfermedades Metabólicas
Funding: 4200000
Reference: CB07/08/0024
Duration: 01/01/2008 - 01/01/2012

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Estela Garcia Gea

Estela Garcia Gea

Research technician
Psychiatry, Mental Health and Addictions
Read more
Erika Ivanna Araya

Erika Ivanna Araya

Postdoctoral researcher
Headache and Neurological Pain
Read more
Santiago Ramon y Cajal Agüeras

Santiago Ramon y Cajal Agüeras

Head of group
Translational Molecular Pathology
Read more
Lorena Viviana Lopez Reyes

Lorena Viviana Lopez Reyes

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.